COVID-19 Vaccine

• 作者: Intazam Khan Tasrina Khan Umair Yaqub Qazi Zameer Shervani
• 来源期刊: 传染病进展(英文)
• 学科: 经济
• 关键词: COVID-19 Vaccine Plasma Therapy COVID-19 Transmission SARS-Cov-2 in Feces COVID-19 in Pets Community Transmission Super Spreader
• 年，卷（期）: crbjzyw_2020,（S1）
• 页码范围: 195-210
• 页数: 16页
• 分类号: F42

摘要

A number of companies have announced the vaccines for COVID-19 pandemic that has caused extreme poverty, famine, and more than a billion people have lost livelihood all across the globe. Mass production of vaccine Sputnik V is underway at different locations to inoculate population in Russia, Philippines, Vietnam, Brazil, Saudi Arab, and United Arab Emirates (UAE), and India. mRNA based vaccine of Pfizer-BioNTech after passing phase 2 trial is ready for testing on thousands of volunteers. Oxford University-AstraZeneca vaccine is also under phase 3 trial in US, Brazil, and India. In September, Novavax Inc.’s vaccine will be ready for phase 3 trial. By early next year, two billions of doses will be ready of Novavax. Moderna Therapeutics conducting vaccine trial on 30 thousands volunteers, results will be known soon. Hundreds of thousand volunteers have registered already for vaccination in US and other parts of the world. SinoVac Biotech Ltd. has prepared a vaccine “CoronaVac” and inoculating volunteers in Indonesia and Brazil. CanSino Biologics Inc. in phase 2 trial on 508 volunteers found a satisfactory immune response to COVID-19 virus. Apart from vaccine preparation and availability, we provided data for therapy and treatment for COVID-19 and transmission and stability aspect of COVID-19 SARS-Cov-2 virus. The data and results presented in this article are very important and useful in containing, treating, and eliminating the pandemic COVID-19.